Roth, AD; Fazio, N; Stupp, R; Falk, S; Bernhard, J; Saletti, P; Köberle, D; Borner, MM; Rufibach, K; Maibach, R; Wernli, M; Leslie, M; Glynne-Jones, R; Widmer, L; Seymour, M; de Braud, F; Swiss, Group for Clinical Cancer Research (2007). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology, 25(22), pp. 3217-23. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2006.08.0135
Full text not available from this repository.This randomized phase II trial evaluated two docetaxel-based regimens to see which would be most promising according to overall response rate (ORR) for comparison in a phase III trial with epirubicin-cisplatin-fluorouracil (ECF) as first-line advanced gastric cancer therapy.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Bernhard, Jürg Theodor, Borner, Markus |
ISSN: |
0732-183X |
ISBN: |
17664469 |
Publisher: |
American Society of Clinical Oncology |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:53 |
Last Modified: |
02 Mar 2023 23:22 |
Publisher DOI: |
10.1200/JCO.2006.08.0135 |
PubMed ID: |
17664469 |
Web of Science ID: |
000248744000008 |
URI: |
https://boris.unibe.ch/id/eprint/22393 (FactScience: 34513) |
Actions (login required)
 |
Edit item |